CD38 as a regulator of cellular NAD: A novel potential pharmacological target for metabolic conditions

Research output: Contribution to journalReview articlepeer-review

105 Scopus citations

Abstract

CD38 is a multifunctional enzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. Recently, CD38 was also identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. Due to the emerging role of NAD as a key molecule in multiple signaling pathways, and metabolic conditions it is imperative to determine the cellular mechanisms that regulate the synthesis and degradation of this nucleotide. In fact, recently it has been shown that NAD participates in multiple physiological processes such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity. The discovery of CD38 as the main cellular NADase in mammalian tissues, and the characterization of its role on the control of cellular NAD levels indicate that CD38 may serve as a pharmacological target for multiple conditions.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalCurrent pharmaceutical design
Volume15
Issue number1
DOIs
StatePublished - 2009

Keywords

  • Aging
  • CD38
  • Metabolic syndrome
  • NAD
  • Obesity
  • SIRT1

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'CD38 as a regulator of cellular NAD: A novel potential pharmacological target for metabolic conditions'. Together they form a unique fingerprint.

Cite this